www.CardioCareLive.com
The Virtual Congress on Cardiovascular Disease
Translating Science into Practice: Recent Advances Across the Spectrum of Cardiology Care
Presented by the Johns Hopkins University School of Medicine.
Supported by educational grants from Abbott Laboratories, AstraZeneca, Daiichi Sankyo, Inc, Lilly
USA, LLC, Roche Diagnostics, Sanofi-Aventis, St. Jude Medical and Thoratec Corporation.
Tuition
Complimentary
Date of Release: May 14, 2010
Date of Expiration: May 14, 2011
Estimated Time to Completion
Each activity will take approximately sixty minutes to complete, for a total of 15 hours.
Course Director
Roger S. Blumenthal, MD, Professor of Medicine, Division of Cardiology at The Johns Hopkins University
School of Medicine, Director, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease
Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing
Medical Education to provide continuing medical education for physicians.
Credit Designation Statements
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 15.0
AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their
participation in the activity.
The University of Tennessee College of Pharmacy is accredited by the Accreditation
Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful
completion of the four sessions designated for CEU credit, as highlighted on the agenda, will provide up to four
home study (H) CE credit (4.0 CEU), and will be available upon successful completion of the program. Please
note that each knowledge-based session will provide a statement for one (1.0) home study (H) CE credit.
Successful completion includes participating in the program, completing a program evaluation form and a posttest with a score of at least 70%. If your score is less than 70% on the post-test, you will be allowed to complete
the post-test one additional time.
ACPE Program Numbers: 064-999-10-225-H01-P,064-999-10-226-H01-P, 064-999-10-227-H01-P, 064-99910-228-H01-P
Release Date: May 14, 2010
Expiration Date May 14, 2011
Grievance Policy: A participant, sponsor, faculty member or other individual wanting to file a grievance with
respect to any aspect of a program sponsored or co-sponsored by the UTCOP may contact the Associate Dean
for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45
days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can
be made for a second level review.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational
activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Physician assistants may receive a maximum of 15 hours of Category 1 credit for completing this program.
This activity has been reviewed and is acceptable for up to 12.5 Elective credits by the American Academy of
Family Physicians.
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 CME Credit(s)™ from
organizations accredited by ACCME
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 CME Credit(s)™ from
organizations accredited by ACCME
Johns Hopkins Statement of Responsibility
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific
integrity of this CME activity.
Intended Audience
Cardiologists, primary care and family physicians, endocrinologists, cardiac imaging specialists, nurses,
diabetes educators, physician assistants, pharmacists, and other healthcare professionals.
Prerequisites
There are no prerequisites.
Statement of Need
Cardiovascular (CV) risk was identified as one of the top priority health care conditions. Our goal is to provide
the opportunity for physicians to learn and connect with world-class experts in cardiology and thousands of
their peers in real time - helping to improve the care of patients with CV risk worldwide. Cardiovascular disease
(CVD) is the leading cause of death in the US, primarily due to the effects of heart disease and stroke. it is
estimated that 785,000 Americans will have a new coronary attack in 2010 and approximately 795,000 will
experience a new or recurrent stroke.
Learning Objectives
After attending this activity, the participant will demonstrate the ability to:
• Interpret and apply recent guidelines to the management of their patients with hypertension, dyslipidemia, and
diabetes. Choosing the appropriate combinations of medical therapies for each patient and using expert
recommended strategies to optimize patient compliance
• Identify and manage atherosclerotic conditions using medical and interventional strategies that apply current
evidence-based best practice
• Apply recent guideline changes and utilize new therapies to design individualized management plans for
patients experiencing acute coronary syndromes
• Choose and utilize cardiovascular risk scoring systems that are appropriate and effective decision-making
tools for specific patient populations within their practices
• Design effective therapeutic plans for atrial fibrillation patients based on recent clinical evidence and expert
recommended guidelines
• Assess new medical and interventional therapies for heart failure and incorporate them into current evidencebased management practices
Course Format
Sessions are approximately sixty minutes and will be delivered in the form of video webcasts from faculty at
www.CardioCareLive.com. If you have participated in any of the live sessions, you will not be eligible to
receive on-demand credit for that particular session. We encourage you to review all sessions, regardless of
your previous participation.
Post-Test and Evaluation
After each presentation participants will be presented with a post-test evaluation. Upon completion of both,
participants receiving a grade of 70% or more will receive a CME certificate via email and US mail. Physicians
must document amount of time they spent in the activity.
Disclaimer Statement
The opinions and recommendations expressed by faculty and other experts whose input is included in this
program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins
University School of Medicine name implies review of educational format design and approach. Please review
the complete prescribing information of specific drugs or combination of drugs, including indications,
contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Expiration Date
The expiration date for access to enduring materials is May 14, 2011, or one year from the end date of live
event, which is May 14, 2010.
Internet CME Policy
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is
committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME
maintains its Internet site as an information resource and service for physicians, other health professionals and
the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your
personal and credit information confidential when you participate in a CME Internet based program. Your
information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME
program. CME collects only the information necessary to provide you with the services that you request.
Full Disclosure Policy Affecting CME Activities
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the
policy of The Johns Hopkins University School of Medicine to require the disclosure of the existence of any
relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s)
of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the
following:
NAME
COMPANY
Hugh Calkins, MD
Grants/Research Support: Biosense Webster
Consultant: Sanofi Aventis; Ablation Frontiers, Biosense Webster; Medtronic; Cyber
Heart Honorarium: Boston Scientific
Christopher Cannon,
MD
Grant/Research Support: Accumetrics; AstraZeneca; Bristol-Myers Squibb/Sanofi
Aventis Partnership; GlaxoSmithKline; Intekrin Therapeutics; Merck; Novartis;
Takeda
Consulting: Scientific Advisory Board (but funds donated to charity) ; Bristol-Myers
Squibb/Sanofi Aventis
Other Financial/Material Support: Clinical Advisor, equity in Automedics Medical
Systems
Keith Ferdinand, MD,
FACC, FAHA
Grants/Research Support: Novartis; Daiichi-Sankyo
Consultant: Novartis; Daiichi-Sankyo; Forest; AstraZeneca; Merck
Honorarium: Novartis; AstraZeneca
Speakers Bureau: AstraZeneca; Forest
David R. Holmes, Jr.,
MD
Other Financial/Material Support: Both Mayo Clinic and I have a financial interest in
technology related to this research. That technology has been licensed to Atritech
and Mayo Clinic and I have a contractual right to receive future royalties from this
license. To date, no royalties have been received by either Mayo Clinic or me.
James Januzzi, MD
Grants/Research Support: Roche; Siemens; Critical Diagnostics
Consultant: Roche; Critical Diagnostics
Peter O. Kwiterovich,
MD
Grants/Research Support: Pfizer, Inc.; Abbott, Inc.; Schering Plough;
SmithKlineBeecham
Consultant: Merck; Schering Plough
Honorarium: Merck; Schering Plough
Speaker Bureau: Merck (non-commercial talks only)
Leslie Miller, MD
Grants/Research Support: Thoratec; Heartware
Consultant: Heartware ? unpaid; Thoratec
Honorarium: Thoratec
Richard Nesto, MD
Consultant: GlaxoSmithKline; Sanofi-Aventis
Paul Ridker, MD,
MPH
Grants/Research Support: Astra Zeneca; Novartis; Sanofi Aventis
Consultant: Vascular Biogenics; Siemens; Novartis; Astra Zeneca; Merck
Patent Royalties: Brigham and Women?s Hospital
Marc Sabatine, MD,
MPH
Grants/Research Support: Astra Zeneca; Sanofi Aventis; Schering-Plough
Scientific Advisory Board: Bristol-Myers Squibb; Sanofi Aventis
Honorarium: Eli Lilly
Gregg W. Stone, MD
Honorarium: Bristol-Myers Squibb/Sanofi Aventis; AstraZeneca; Boston Scientific;
Abbott Vascular
Matthew Weir, MD
Ad-Hoc Scientific Advisor: Novartis; Daiichi-Sankyo; Boehringer-Ingelheim
Nathan Wong, PhD
Grants/Research Support: Bristol-Myers Squibb; Novartis; Forest Pharmaceuticals
All other speakers have indicated that they have not received financial support for consultation, research,
evaluation or have a financial interest relevant to their presentation.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the
institution which receives the grants, typically through the Office of Research Administration. Individual
investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may
receive salary or other support from the institution to support their effort on the project(s).
OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of
drugs or products:
NAME
COMPANY
Christopher Cannon, MD
ticagrelor
David R. Holmes, Jr., MD
Atritech, Watchman Device
James Januzzi, MD
natriuretic peptides
Leslie Miller, MD
HeartWare device
Marc Sabatine, MD, MPH
clopidogrel, prasugrel, ticagrelor
All other speakers have indicated that they will not reference unlabeled/unapproved uses of drugs or products.